geon:scientist with his MD/PhD in immunology and cell biology from SUNY Downstate Medical Center, and his residency at Columbia University, where he worked assidu ously in the brain tumor research laboratory of Dr. Jeffrey Bruce. Interestingly, Andy's first citation in the literature was in the Journal of Neurosurgery on "Antiglioma cyto toxic immune response" while he was still a medical stu dent in Brooklyn. 4 Throughout his career, Andy was a highly prolific au thor with over 245 peerreviewed publications. His pub lications as first or corresponding author can be found in many specialty journals, such as Journal of Neurosurgery, Neurosurgery, and World Neurosurgery; neurooncology journals including Neuro-Oncology and Journal of NeuroOncology; and basic science journals including PLoS One, Journal of Translational Medicine, Cancer, Oncogene, and Nature Medicine. A review of the topics on which Andy wrote clearly demonstrates his focus on human brain tumors of all types and research on immunothera py of human gliomas. His name is associated with many of the best contemporary clinical series on patients with intramedullary spinal cord tumors, vestibular schwanno mas, meningiomas, gliosarcomas, hemangiopericytomas, pineocytomas, chordomas, ependymomas, choroid plexus tumors, and glioblastoma multiforme (GBM).
In the laboratory, Andy used his research training in immunology and immunotherapy to develop a vaccine for patients with malignant glioma-an extraordinary feat ac complished by very few neurosurgeons. This vaccine is generated against heat shock proteins (HSPs), which are extracted from patient glioma samples at surgery. What provides the patient specificity for the vaccine is the fact that HSPs act as molecular chaperones for unique bind ing peptides within the tumors. Andy published the "first in human" study of vaccination against high-grade gliomas using autologous tumor peptides bound to the 96kD chaperone protein Research. 3 This was followed by a Phase II study in 41 patients with surgically resectable recurrent GBM, which was published in Neuro-Oncology last year. 1 The results of the HSP96 vaccination in additional clinical trials for patients with GBM will be forthcoming in the near future.
As EditorinChief of the Journal of Neurosurgery, I delighted in seeing Andy's thoughtful and comprehensive reviews of articles that were assigned to him. Oddly, by virtue of the sequential peerreview process of the Journal, several of Andy's reviews came to me after his pass ing on April 13, 2015. Andy's final publication in the Journal, on the impact of time to initiation of chemotherapy on patient survival after resection of newly diagnosed GBM, also appeared in print after he had died. 5 It reminded me that the written and published word survives all of us, and can be used as a partial measure of our accomplishments on earth. Andy's seminal work on human brain tumors and contributions to the literature will undoubtedly be quoted and remembered, now until eternity.
As driven as Andy was as a neurosurgeon to making a difference in the lives of patients with malignant brain tu mors, and becoming a department chair of neurosurgery, Andy was even more committed and devoted to his fam ily. At meetings, he delighted in showing me photographs of his wife, Charlotte, and his children, Julia, Micheline, and Ismail, of whom he was exceedingly proud. While Andy's life on earth was cut all too short, it is clear to me that in the years that he lived, his clock was not set to stan dard time. He defied the definition of time (Fig. 1) through the supernumerary personal and professional accomplish ments that characterized his being. 
